Our preliminary evidence suggested that circulating cfDNA methylation profile as a single assay for MS diagnosis, subtyping, and monitoring and prognosis could potentially complement established blood biomarkers such as NfL and GFAP. The gene discussed is GFAP; the disease is myeloid sarcoma.